The DOI matches its Crossref record; 162 of the 165 references it cites were found in a registry or an index; 194 of the 302 sources its claims cite were checked for support.
Epidemiology of Invasive Candidiasis
Open accessAbstract
Invasive candidiasis (IC) is an increasingly prevalent, costly, and potentially fatal infection brought on by the opportunistic yeast, Candida . Previously, IC has predominantly been caused by C. albicans which is often drug susceptible. There has been a global trend towards decreasing rates of infection secondary to C. albicans and a rise in non- albicans species with a corresponding increase in drug resistance creating treatment challenges. With advances in management of malignancies, there has also been an increase in the population at risk from IC along with a corresponding increase in incidence of breakthrough IC infections. Additionally, the emergence of C. auris creates many challenges in management and prevention due to drug resistance and the organism’s ability to transmit rapidly in the healthcare setting. While the development of novel antifungals is encouraging for future management, understanding the changing epidemiology of IC is a vital step in future management and prevention. Keywords: Candida, epidemiology, resistance, emerging, non- albicans Candida species
Overview
CoChat Summary
TL;DR
Invasive candidiasis remains a costly, morbid, and often fatal infection, with declining *C. albicans* proportions, rising non-albicans species, antifungal resistance, breakthrough infections, and the emergence of multidrug-resistant *C. auris*. This review synthesizes global epidemiology, diagnostics, burden, species distribution, resistance trends, management, and prevention.
Key findings
- Candidemia causes an estimated 22,000 infections annually in the United States and is the second most common healthcare-associated bloodstream infection nationally; all-cause in-hospital mortality has been reported as high as 36% in the US, 38–42% at 30 days in Europe, ~40% in Asia, 33–60% in MENA, and 30–70% in South America.
- The proportion of *C. albicans* has fallen from 70–80% in the 1980–1990s to 40–60% in most areas; in ECMM studies, *C. albicans* decreased from 56.4% (1997–1999) to 54% (2006–2008) to 46.0% (2018), while *C. glabrata* rose from 13.9% to 21.0%.
- Resistance is increasing: CDC surveys report *C. glabrata* fluconazole resistance of 7–11% and echinocandin resistance of 2–8%; *C. parapsilosis* fluconazole resistance exceeds 50% in some series and is 4–10% in the US; *C. auris* shows fluconazole resistance in 70–90% of isolates, echinocandin resistance up to 7%, amphotericin B resistance up to 35%, and pan-resistance most commonly in India/South Asia (3%).
- Breakthrough *Candida* infections occur in fewer than 10% of at-risk patients but can constitute up to 40% of all *Candida* infections in selected series; 30-day mortality is similar to de novo infections (~30%). Blood cultures have only ~50% sensitivity for invasive candidiasis; T2Candida has 91% sensitivity and 94% specificity, while 1,3-β-D-glucan sensitivity averages ~85% but specificity is often below 60%.
Methods
- Narrative review of invasive candidiasis epidemiology, diagnostics, burden, geographic species differences, emerging species, breakthrough infections, antifungal susceptibility, management, antifungal pipeline, and infection control.
- Evidence is drawn from published literature, including population-based surveillance, meta-analyses, multicenter ECMM/SENTRY/CDC/TRANSNET studies, clinical trials, and guidelines; no new primary data are presented.
- Main analysis is qualitative synthesis; no systematic review search strategy, risk-of-bias assessment, or quantitative pooling is described.
Limitations
- Stated: current diagnostics have limited sensitivity/specificity that affect epidemiologic assessment; intra-abdominal candidiasis lacks standardized definitions; there are no population-based data sources for Asia, the Middle East, Africa, or Latin America; most IC studies are single-center or smaller multicenter analyses; candidemia is generally not reportable, so reporting is voluntary; lack of standardized methodologies and denominators limits comparisons.
- Stated: the overall burden of IC is likely underestimated because of global surveillance gaps and diagnostic performance limitations.
- Evident: as a narrative review, it does not provide a systematic search, formal quality appraisal, or quantitative synthesis, so conclusions may inherit publication and surveillance biases from the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
104 Valid · 10 Not valid · 40 Not checked · 16 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Partly supportedcites [122] Lockhart, 2017, Clin Infect Dis sourceExperimental — accuracy not yet measured
The Results (Antifungal Susceptibility Testing; page unavailable) report that the two isolates resistant to all three major antifungal classes were both from India, supporting the geographic comparison within this study’s sample. The paper reports 4% of all tested isolates—not 3% of Indian isolates—and its samples from four countries do not establish how common this resistance is worldwide. (LLM, conf=0.88)
- Partly supportedcites [123] Chowdhary, 2017, PLoS Pathog sourceExperimental — accuracy not yet measured
In “Is antifungal resistance in C. auris a therapeutic challenge?” (page unavailable), the paper reports that a low number (4%) of isolates resist all antifungal classes. It does not give the claimed 3% figure for India or establish that resistance to all three classes is less common elsewhere. (LLM, conf=0.84)
- Disputedcites [124] Chowdhary, 2018, J Antimicrob Chemother sourceExperimental — accuracy not yet measured
The JAC section reports that 2% of the Indian isolates had combined azole and echinocandin resistance. Resistance to all three classes could not therefore occur in 3% of those isolates. The Discussion’s 3% figure refers to echinocandin resistance alone among US isolates, and the paper does not establish that triple-class resistance is most common in India. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Historically this organism has been pan-susceptible to triazoles, echinocandins, and amphotericin B.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Results sections report fluconazole resistance in C. tropicalis isolates, including 9.2% in the Asia-Pacific region, and echinocandin resistance of 0.5%–0.7% during the surveillance period. That contradicts pan-susceptibility across those drug classes. The Methods list the agents tested and do not include amphotericin B, so the paper does not establish that part of the claim. The supplied copy gives section labels but no page numbers. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
Table 4 (Results, Fluconazole Resistance by Geographic Area and Species) reports 3.7% fluconazole resistance for North American C. parapsilosis isolates in 2006–2016, rather than a US rate of 4–10%. It reports 4.6% in Europe and 4.3% in Latin America—only slightly above the North American rate, not much higher. The table does not give a separate rate for Japan. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Could not verifycites [103] Adam, 2021, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Antifungal Susceptibility Testing section reports 4%–7% fluconazole nonsusceptibility in C. parapsilosis isolates from Switzerland, not resistance rates in the US. A search for US C. parapsilosis fluconazole resistance rates found no passage giving the claimed 4%–10% range. (LLM, conf=0.76)
- Partly supportedcites [112] Arastehfar, 2020, J Fungi sourceExperimental — accuracy not yet measured
Section 6.3 reports fluconazole-resistant C. parapsilosis, and section 9 says it has been observed in the USA. Neither passage gives a US resistance rate of 4–10%; the percentages in section 6.3 refer to other regions. (LLM, conf=0.83)
- Could not verifycites [120] Pfaller, 2011, J Clin Microbiol sourceExperimental — accuracy not yet measured
The Results and Discussion passages report susceptibility of Aspergillus species to itraconazole, posaconazole, and voriconazole; page numbers are unavailable in our copy. Searches for fluconazole, C. parapsilosis, and the stated geographic comparison found no passage reporting the claimed US resistance rate. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Results (Table 4; page not provided) report C. parapsilosis fluconazole resistance of 3.7% in North America, 4.6% in Europe, 4.3% in Latin America, and 0.6% in Asia-Pacific. Europe and Latin America are only slightly higher than North America, while Asia-Pacific is lower—not the much higher rates claimed. The table does not give separate rates for the US, Japan, or Western Europe. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [103] Adam, 2021, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Discussion says several countries have reported emerging azole resistance in C. parapsilosis. However, it does not identify Japan, Western Europe, or Latin America or compare their fluconazole resistance rates with those in the US. The susceptibility-testing section reports Swiss nonsusceptibility rates of 6%, 7%, and 4% across the study periods, not the claimed international comparison. (LLM, conf=0.76)
- Disputedcites [112] Arastehfar, 2020, J Fungi sourceExperimental — accuracy not yet measured
Section 6.3 (page unavailable) reports 4.6% fluconazole-resistant C. parapsilosis isolates in Latin America—not a rate much higher than the citing sentence’s stated US range of 4–10%. The section does not provide the claimed US rate or comparable rates for Japan and Western Europe. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Could not verifycites [120] Pfaller, 2011, J Clin Microbiol sourceExperimental — accuracy not yet measured
The Results and Discussion passages report susceptibility of Aspergillus species to itraconazole, posaconazole, and voriconazole; no page numbers are provided. Searches for C. parapsilosis, fluconazole, and the claimed regional resistance rates found no passage addressing that comparison. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Ibrexafungerp is currently only FDA approved as oral therapy for vulvovaginal candidiasis, although clinical trials for invasive candidiasis step-down therapy, refractory candidiasis, and C. auris are ongoing.149,156–159”
§ Epidemiology of Invasive Candidiasis > The Antifungal Pipeline for IC
What the sources say
- Partly supportedcites [149] Seiler, 2021, Curr Fungal Infect Rep sourceExperimental — accuracy not yet measured
The Ibrexafungerp section (Agents in Phase III Clinical Trials; page unavailable) describes oral ibrexafungerp in ongoing trials, and the References list a phase III study for vulvovaginal candidiasis. Our copy does not state that ibrexafungerp is FDA approved, or that vulvovaginal candidiasis is its only approved indication. (LLM, conf=0.83)
- Supportedcites [156] Hoenigl, 2021, Drugs source
The Ibrexafungerp section states that the FDA approved ibrexafungerp for oral use in patients with vulvovaginal candidiasis. Its Future Role subsection says other approvals were still expected, supporting the claim that this was its only FDA-approved use at the time covered by the paper. (LLM, conf=0.92)
- Supportedcites [157] Mccarthy, 2022, Drugs R D source
The Abstract states that the FDA approved ibrexafungerp for vulvovaginal candidiasis following trials of oral treatment. The Introduction identifies it as an oral formulation, while Future Directions treats other indications as under investigation rather than approved. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [158] Spec, 2019, J Antimicrob Chemother source
- Disputedcites [159] Jallow, 2021, J Fungi sourceExperimental — accuracy not yet measured
Section 8, “Indications and Usage,” says the FDA had accepted a new drug application for oral ibrexafungerp to treat vulvovaginal candidiasis; it does not say the drug was approved. Section 9, “Conclusions,” says an FDA action date was still pending and a US commercial launch was planned, contrary to the claim that approval had already been granted. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
90 more claims · 59 with their cited sources checked
Create a free account to see all 170 claims and to verify the 4 references still open.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 58
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Epidemiology of Invasive Candidiasis > Geographic Differences of Invasive Candidiasis
“to 2018 (21.4%)56”
§ Epidemiology of Invasive Candidiasis > Geographic Differences of Invasive Candidiasis
“| C. glabrata | 13.9% | 13.8% | 21.0% |”
Citations
Cites
Guidelines for the Prevention of Intravascular Catheter-related Infections
O'Grady, N. P., Alexander, M., Burns, L. A., Dellinger, E. P., Garland, J., Heard, S. O., Lipsett, P. A., Masur, H., Mermel, L. A., Pearson, M. L., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir257 · Cited by 4,699
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · cited 6×
“125,164 C. auris outbreaks in healthcare facilities has recently seen an increase, greatly facilitated by the COVID pandemic with the large numbers of critically ill, mechanically ventilated patients and likely breaches in infection control practices.”
BackgroundInfluentialSelf-citationEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“33 More recent data using US electronic medical records showed there was no significant change in the incidence between 2009–2017, with an overall incidence of inpatient IC of 90 per 100,000 hospitalizations.”
MethodDonnelly, J. P., Chen, S. C., Kauffman, C. A., Steinbach, W. J., Baddley, J. W., Verweij, P. E., Clancy, C. J., Wingard, J. R., Lockhart, S. R., Groll, A. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1008 · Cited by 2,917
Self-citationLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Self-citationGlobal incidence and mortality of severe fungal disease
Denning, D. W. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00692-8 · Cited by 1,640
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636 · cited 8×
“18,62,66 However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.”
BackgroundMethodInfluentialSelf-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“92 Less common species such as C. lusitaniae and C. guilliermondii have also been reported.”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Changes in prevalence of health care-associated infections in U.S. hospitals
Magill, S. S., O’Leary, E., Janelle, S. J., Thompson, D. L., Dumyati, G., Nadle, J., Wilson, L. E., Kainer, M. A., Lynfield, R., Greissman, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801550 · Cited by 1,249 · cited 1×
“26 A higher incidence of candidemia has been reported among older adults, males, and those of black/African-American ethnicity.”
BackgroundCornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 1×
“133 ,135,136 The IDSA recommends consideration of fluconazole or echinocandin prophylaxis for high-risk ICU patients in units with >5% rate of invasive candidiasis.”
BackgroundClinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis
Wilson, M. R., Sample, H. A., Zorn, K. C., Arevalo, S., Yu, G., Neuhaus, J., Federman, S., Stryke, D., Briggs, B., Langelier, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803396 · Cited by 1,067 · cited 1×
“23 There is limited data thus far for the diagnosis of invasive candidiasis by this methodology, although early reports show potential.”
Guidelines for the prevention of intravascular catheter-related infections
O'Grady, N. P., Alexander, M., Burns, L. A., Dellinger, E. P., Garland, J., Heard, S. O., Lipsett, P. A., Masur, H., Mermel, L. A., Pearson, M. L., et al. (2011) · American Journal of Infection Control · doi:10.1016/j.ajic.2011.01.003 · Cited by 1,066
Guo, Z.-D., Wang, Z.-Y., Zhang, S.-F., Li, X., Li, L., Li, C., Cui, Y., Fu, R.-B., Dong, Y.-Z., Chi, X.-Y., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200885 · Cited by 1,065
Anidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
Self-citationCandida albicans morphogenesis and host defence: discriminating invasion from colonization
Gow, N. A. R., van de Veerdonk, F. L., Brown, A. J. P., & Netea, M. G. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2711 · Cited by 888
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825 · cited 8×
“18,62,66 However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.”
BackgroundInfluentialA Homozygous CARD9 Mutation in a Family with Susceptibility to Fungal Infections
Glocker, E.-O., Hennigs, A., Nabavi, M., Schäffer, A. A., Woellner, C., Salzer, U., Pfeifer, D., Veelken, H., Warnatz, K., Tahami, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810719 · Cited by 800
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
Self-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 1×
“111 A general consensus suggests that echinocandin resistance rates are generally higher in academic institutions compared to community-based medical centers, however this is not true across all centers.”
BackgroundChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750 · cited 1×
“122,123 122–124 Because of the potential for person-to-person transmission with C. auris , infection prevention measures are key to preventing nosocomial spread.”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Self-citationClancy, C. J., & Nguyen, M. H. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit006 · Cited by 688
Global trends in the distribution of Candida species causing candidemia
Guinea, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12539 · Cited by 680 · cited 1×
“59,60 The changes in distribution of non-albicans Candida spp. also have strong regional variations and it is imperative to understand local epidemiologic patterns when empiric treatment is prescribed rather than relying on regional assessments.”
BackgroundEffect of Daily Chlorhexidine Bathing on Hospital-Acquired Infection
Climo, M. W., Yokoe, D. S., Warren, D. K., Perl, T. M., Bolon, M., Herwaldt, L. A., Weinstein, R. A., Sepkowitz, K. A., Jernigan, J. A., Sanogo, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113849 · Cited by 653
Immune defence against Candida fungal infections
Netea, M. G., Joosten, L. A. B., van der Meer, J. W. M., Kullberg, B.-J., & van de Veerdonk, F. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3897 · Cited by 642
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Self-citationAutoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy
Perheentupa, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2611 · Cited by 604 · cited 1×
“…in those with polymorphisms in specific genomic regions particularly in those with STAT1 gain of function mutations 12 or in autosomal recessive polyglandular autoimmune syndrome type I. 13 In contrast, invasive disease primarily occurs in those with a clear breach in host defenses (Figure 1).”
BackgroundChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 1×
“122,123 122–124 Because of the potential for person-to-person transmission with C. auris , infection prevention measures are key to preventing nosocomial spread.”
BackgroundChanges in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547 · cited 2×
“44 Furthermore, most IC studies are single-center or smaller multi-center analyses.”
BackgroundInfluentialTortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509
Nosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502 · cited 1×
“While the proportion of C. albicans was 70–80% in the 1980–1990s, 54 it has now declined to 40–60% in most geographic areas.”
BackgroundCOVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482 · cited 2×
“34 40 Candidemia in these patients with COVID-19 but no other underlying comorbidities likely resulted from healthcare-related exposures related to severe COVID-19 infection.”
BackgroundSelf-citationThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · cited 2×
“150 It has oral bioavailability of 35–50% and good systemic distribution except for the CNS. 156–159 Lastly, fosmanogepix is another encouraging novel antifungal.”
BackgroundSelf-citationEstimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438 · cited 1×
“49 The estimated total US economic burden of IC is $1.8 billion.”
BackgroundInfluentialSelf-citationThe WHO fungal priority pathogens list as a game-changer
Fisher, M. C., & Denning, D. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00861-x · Cited by 399
Climate change and the emergence of fungal pathogens
Nnadi, N. E., & Carter, D. A. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009503 · Cited by 373 · cited 1×
“69,70 The most prominent example is C. auris , which is theorized to have evolved from a plant saprophyte and possibly became a human pathogen after adaptation to higher temperatures.”
BackgroundCleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366 · cited 1×
“27,51,52 In Europe, the 30-day mortality rate of IC was slightly higher at 38–42%.”
BackgroundSelf-citationLortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362
Ferwerda, G., Meyer-Wentrup, F., Kullberg, B.-J., Netea, M. G., & Adema, G. J. (2008) · Cellular Microbiology · doi:10.1111/j.1462-5822.2008.01188.x · Cited by 362
Hoyer, L. L., Green, C. B., Oh, S.-H., & Zhao, X. (2008) · Medical Mycology · doi:10.1080/13693780701435317 · Cited by 356
Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis
Koehler, P., Stecher, M., Cornely, O. A., Koehler, D., Vehreschild, M. J. G. T., Bohlius, J., Wisplinghoff, H., & Vehreschild, J. J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.024 · Cited by 336 · cited 2×
“31,43 Currently, there are no population-based data sources for Asia, the Middle East, Africa, or Latin America.”
BackgroundResultUllmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334 · cited 1×
“131 The IDSA recommends consideration of empiric antifungal therapy in deteriorating patients with risk factors and surrogate markers suggestive of infection.”
BackgroundGlobal epidemiology of emerging Candida auris
Rhodes, J., & Fisher, M. C. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.05.008 · Cited by 315 · cited 1×
“75,76 In contrast to C. auris , which truly is an emerging pathogen, Candida spp. that were defined before as “emerging” 77 (ie, C. kefyr, C. guilliermondii, C. lusitaniae, C. dubliniensis, C. famata, C. inconspicua, C. rugosa, C. norvegiensis ), may have in fact already “emerged” due to better…”
ResultEmerging and Emerged Pathogenic Candida Species: Beyond the Candida albicans Paradigm
Papon, N., Courdavault, V., Clastre, M., & Bennett, R. J. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003550 · Cited by 314 · cited 1×
“75,76 In contrast to C. auris , which truly is an emerging pathogen, Candida spp. that were defined before as “emerging” 77 (ie, C. kefyr, C. guilliermondii, C. lusitaniae, C. dubliniensis, C. famata, C. inconspicua, C. rugosa, C. norvegiensis ), may have in fact already “emerged” due to better…”
ResultCleveland, A. A., Harrison, L. H., Farley, M. M., Hollick, R., Stein, B., Chiller, T. M., Lockhart, S. R., & Park, B. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120452 · Cited by 304 · cited 1×
“…more nuanced assessment using data from active population-based surveillance showed the incidence of candidemia decreased from 2008 to 2017 across multiple US sites, 25,27,35 with a coincident increase in the incidence of IC from non-blood sources, including abdominal sterile sites, from 2009–2017.”
BackgroundSelf-citationWorsening Spread of Candida auris in the United States, 2019 to 2021
Lyman, M., Forsberg, K., Sexton, D. J., Chow, N. A., Lockhart, S. R., Jackson, B. R., & Chiller, T. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3469 · Cited by 287 · cited 1×
“70,71,73 As a result, C. auris has”
Self-citationMcCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.013 · Cited by 285 · cited 1×
“14”
Self-citationHealey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276
Bassetti, M., Giacobbe, D. R., Vena, A., Trucchi, C., Ansaldi, F., Antonelli, M., Adamkova, V., Alicino, C., Almyroudi, M.-P., Atchade, E., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2497-3 · Cited by 270 · cited 6×
“31,43 Currently, there are no population-based data sources for Asia, the Middle East, Africa, or Latin America.”
BackgroundInfluentialCandidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260 · cited 2×
“133 ,135,136 The IDSA recommends consideration of fluconazole or echinocandin prophylaxis for high-risk ICU patients in units with >5% rate of invasive candidiasis.”
BackgroundSelf-citationDaneshnia, F., de Almeida Júnior, J. N., Ilkit, M., Lombardi, L., Perry, A. M., Gao, M., Nobile, C. J., Egger, M., Perlin, D. S., Zhai, B., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00067-8 · Cited by 257
Self-citationArendrup, M. C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M. C., Meletiadis, J., Guinea, J., Friberg, N., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.06.007 · Cited by 238
ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients
Martin-Loeches, I., Antonelli, M., Cuenca-Estrella, M., Dimopoulos, G., Einav, S., De Waele, J. J., Garnacho-Montero, J., Kanj, S. S., Machado, F. R., Montravers, P., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05599-w · Cited by 235
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229 · cited 2×
“160 Results from a Phase 2 clinical trial for patients with candidemia from C. auris demonstrated safety and efficacy of fosmanogepix.”
BackgroundEnvironmental Isolation of Candida auris from the Coastal Wetlands of Andaman Islands, India
Arora, P., Singh, P., Wang, Y., Yadav, A., Pawar, K., Singh, A., Padmavati, G., Xu, J., & Chowdhary, A. (2021) · mBio · doi:10.1128/mbio.03181-20 · Cited by 223 · cited 1×
“72 C. auris is now a global human threat, particularly in healthcare settings, causing large outbreaks in ICUs in India, Southern Europe, the United Kingdom, Brazil and the United States.”
BackgroundCornely, O. A., Hoenigl, M., Lass‐Flörl, C., Chen, S. C. ‐., Kontoyiannis, D. P., Morrissey, C. O., Thompson, G. R., & for the Mycoses Study Group Education and Research Consortium (MSG‐ERC) and the European Confederation of Medical Mycology (ECMM) (2019) · Mycoses · doi:10.1111/myc.12960 · Cited by 215
Self-citationBetts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz‐Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz‐Palacios, G., Young, J. H., Baddley, J. W., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598933 · Cited by 214
Timsit, J.-F., Azoulay, E., Schwebel, C., Charles, P. E., Cornet, M., Souweine, B., Klouche, K., Jaber, S., Trouillet, J.-L., Bruneel, F., et al. (2016) · JAMA · doi:10.1001/jama.2016.14655 · Cited by 198
Toda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., et al. (2019) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6808a1 · Cited by 198 · cited 5×
“27,51,52 In Europe, the 30-day mortality rate of IC was slightly higher at 38–42%.”
BackgroundInfluentialThompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02324-8 · Cited by 192 · cited 1×
“154,155 It is similar in structure to anidulafungin but with an extended half-life allowing weekly administration which will improve its suitability for outpatient therapy.”
BackgroundSelf-citationBreakthrough invasive fungal infections: Who is at risk?
Jenks, J. D., Cornely, O. A., Chen, S. C. ‐., Thompson, G. R., & Hoenigl, M. (2020) · Mycoses · doi:10.1111/myc.13148 · Cited by 191
Self-citationAndes, D. R., Safdar, N., Baddley, J. W., Alexander, B., Brumble, L., Freifeld, A., Hadley, S., Herwaldt, L., Kauffman, C., Lyon, G. M., et al. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12613 · Cited by 182
Self-citationZhu, W., Phan, Q. T., Boontheung, P., Solis, N. V., Loo, J. A., & Filler, S. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117676109 · Cited by 180
Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study
Tan, B. H., Chakrabarti, A., Li, R. Y., Patel, A. K., Watcharananan, S. P., Liu, Z., Chindamporn, A., Tan, A. L., Sun, P.-L., Wu, U.-I., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.06.010 · Cited by 176
Okada, S., Asano, T., Moriya, K., Boisson-Dupuis, S., Kobayashi, M., Casanova, J.-L., & Puel, A. (2020) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00847-x · Cited by 171 · cited 1×
“…mucocutaneous infection occurs in those with polymorphisms in specific genomic regions particularly in those with STAT1 gain of function mutations 12 or in autosomal recessive polyglandular autoimmune syndrome type I. 13 In contrast, invasive disease primarily occurs in those with a clear breach…”
BackgroundFungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management
Thompson, G. R., Jenks, J. D., Baddley, J. W., Lewis, J. S., Egger, M., Schwartz, I. S., Boyer, J., Patterson, T. F., Chen, S. C. ‐., Pappas, P. G., et al. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-23 · Cited by 165
Self-citationUllmann, A. J., Cornely, O. A., DonneNy, J. P., Akova, M., Arendrup, M. C., Arıkan-Akdağlı, S., Bassetti, M., Billé, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12037 · Cited by 164
Oropharyngeal candidiasis in the era of antiretroviral therapy
Thompson, G. R., Patel, P. K., Kirkpatrick, W. R., Westbrook, S. D., Berg, D., Erlandsen, J., Redding, S. W., & Patterson, T. F. (2010) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2009.11.026 · Cited by 164
Self-citationBurden of Candidemia in the United States, 2017
Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa193 · Cited by 163 · cited 4×
“25,40,41,55,61 Comparatively, the proportion of C. parapsilosis has increased in Asia (including Japan and China), Latin America (including Brazil) and Southern Europe, 31,62–65 and the proportion of C. tropicalis has increased particularly in Latin America, and large parts of Asia.”
BackgroundInfluentialSelf-citationChanging epidemiology of candidaemia in Australia
Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw422 · Cited by 163 · cited 2×
“25,40,41,55,61 Comparatively, the proportion of C. parapsilosis has increased in Asia (including Japan and China), Latin America (including Brazil) and Southern Europe, 31,62–65 and the proportion of C. tropicalis has increased particularly in Latin America, and large parts of Asia.”
BackgroundInfluentialOstrosky-Zeichner, L., Shoham, S., Vazquez, J., Reboli, A., Betts, R., Barron, M. A., Schuster, M., Judson, M. A., Revankar, S. G., Caeiro, J. P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu074 · Cited by 160 · cited 1×
“125 ,137 A Cochrane review of prophylaxis in non-neutropenic ICU patients did not find an effect on mortality but did note a significant decrease in invasive fungal infection.”
BackgroundSelf-citationQuantitation of Candida CFU in Initial Positive Blood Cultures
Pfeiffer, C. D., Samsa, G. P., Schell, W. A., Reller, L. B., Perfect, J. R., & Alexander, B. D. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00609-11 · Cited by 158 · cited 1×
“…methods, in particular the collected blood volume as during candidemia there is typically less than one colony forming unit of Candida per mL. 17 However, blood cultures cannot be relied upon in all cases of IC given approximately one-third of patients with IC are categorized as having…”
MethodHoenigl, M., Salmanton-García, J., Egger, M., Gangneux, J.-P., Bicanic, T., Arikan-Akdagli, S., Alastruey-Izquierdo, A., Klimko, N., Barac, A., Özenci, V., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00872-6 · Cited by 152 · cited 2×
“25,55,56 While that decreasing trend is ubiquitous, with the series of multicenter European Confederation of Medical Mycology (ECMM) Candida studies showing the proportion of C. albicans causing candidemia decreased from 56.4% in 1997–1999, 57 to 54% in 2006–2008, 58 to 46.2% in 2018 56 with…”
BackgroundInfluentialSelf-citationIntra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment
Vergidis, P., Clancy, C. J., Shields, R. K., Park, S. Y., Wildfeuer, B. N., Simmons, R. L., & Nguyen, M. H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153247 · Cited by 150
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145 · cited 3×
“62,103,112 In general, voriconazole has been considered the best oral option for C. krusei infections, however, recent population surveys have demonstrated emerging resistance rates to voriconazole, approximating 10% in some regions of the world.”
BackgroundEnvironmental Candida auris and the Global Warming Emergence Hypothesis
Casadevall, A., Kontoyiannis, D. P., & Robert, V. (2021) · mBio · doi:10.1128/mbio.00360-21 · Cited by 145 · cited 2×
“70,71,73 As a result, C. auris has”
ResultThe Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic
Seagle, E. E., Jackson, B. R., Lockhart, S. R., Georgacopoulos, O., Nunnally, N. S., Roland, J., Barter, D. M., Johnston, H. L., Czaja, C. A., Kayalioglu, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab562 · Cited by 141 · cited 2×
“25,40,41,55,61 Comparatively, the proportion of C. parapsilosis has increased in Asia (including Japan and China), Latin America (including Brazil) and Southern Europe, 31,62–65 and the proportion of C. tropicalis has increased particularly in Latin America, and large parts of Asia.”
BackgroundSelf-citationKlingspor, L., Tortorano, A. M., Peman, J., Willinger, B., Hamal, P., Sendid, B., Velegraki, A., Kibbler, C., Meis, J. F., Sabino, R., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.08.011 · Cited by 137
Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016–20171
van Schalkwyk, E., Mpembe, R. S., Thomas, J., Shuping, L., Ismail, H., Lowman, W., Karstaedt, A. S., Chibabhai, V., Wadula, J., Avenant, T., et al. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190040 · Cited by 137
Sabino, R., Veríssimo, C., Pereira, Á. A., & Antunes, F. (2020) · Microorganisms · doi:10.3390/microorganisms8020181 · Cited by 133
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129 · cited 1×
“150 It has oral bioavailability of 35–50% and good systemic distribution except for the CNS. 156–159 Lastly, fosmanogepix is another encouraging novel antifungal.”
BackgroundKayaaslan, B., Eser, F., Kaya Kalem, A., Bilgic, Z., Asilturk, D., Hasanoglu, I., Ayhan, M., Tezer Tekce, Y., Erdem, D., Turan, S., et al. (2021) · Mycoses · doi:10.1111/myc.13332 · Cited by 126
Xiao, M., Chen, S. C.-A., Kong, F., Xu, X.-L., Yan, L., Kong, H.-S., Fan, X., Hou, X., Cheng, J.-W., Zhou, M.-L., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz573 · Cited by 115
Invasive candidiasis species distribution and trends, United States, 2009-2017
Ricotta, E. E., Lai, Y. L., Babiker, A., Strich, J. R., Kadri, S. S., Lionakis, M. S., Prevots, D. R., & Adjemian, J. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa502 · Cited by 114 · cited 2×
“34 40 Candidemia in these patients with COVID-19 but no other underlying comorbidities likely resulted from healthcare-related exposures related to severe COVID-19 infection.”
BackgroundMastrangelo, A., Germinario, B. N., Ferrante, M., Frangi, C., Li Voti, R., Muccini, C., Ripa, M., COVID-BioB Study Group, Canetti, D., Castiglioni, B., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1594 · Cited by 112
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
The Cava Trem Study Group, León, C., Ruiz-Santana, S., Saavedra, P., Castro, C., Loza, A., Zakariya, I., Úbeda, A., Parra, M., Macías, D., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1324-3 · Cited by 110
Economic Burden of Fungal Diseases in the United States
Benedict, K., Whitham, H. K., & Jackson, B. R. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac097 · Cited by 108
Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021
Kohlenberg, A., Monnet, D. L., Plachouras, D., & Candida auris survey collaborative group (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.46.2200846 · Cited by 108 · cited 2×
“…, where some countries only see isolated cases reported, potentially due to more strict hospital hygiene measures preventing nosocomial transfer and difficult to control outbreaks, 75 while other countries are at a state of emergency due to larger outbreaks with this multi-drug resistant pathogen.”
BackgroundResultBreakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole
Rausch, C. R., DiPippo, A. J., Bose, P., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy406 · Cited by 107
Kullberg, B. J., van 't Wout, J. W., & van Furth, R. (1990) · Infection and Immunity · doi:10.1128/iai.58.10.3319-3324.1990 · Cited by 105
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
Self-citationPfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., & Diekema, D. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02136-10 · Cited by 91 · cited 1×
“62,103,112,120 C. krusei is considered inherently resistant to fluconazole yet demonstrates variable susceptibility to both voriconazole and posaconazole.”
BackgroundAntifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Cortegiani, A., Russotto, V., Maggiore, A., Attanasio, M., Naro, A. R., Raineri, S. M., & Giarratano, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004920.pub3 · Cited by 91 · cited 1×
“138 European guidelines recommend fluconazole prophylaxis in ICU patients with recent abdominal surgery with recurrent perforation or leakage.”
BackgroundBailly, S., Maubon, D., Fournier, P., Pelloux, H., Schwebel, C., Chapuis, C., Foroni, L., Cornet, M., & Timsit, J. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.09.041 · Cited by 90
Viehman, J. A., Clancy, C. J., Clarke, L., Shields, R. K., Silveira, F. P., Kwak, E. J., Vergidis, P., Hughes, C., Humar, A., & Nguyen, M. H. (2016) · Transplantation · doi:10.1097/tp.0000000000001356 · Cited by 90 · cited 1×
“80,84,85 In the largest study to date, the TRANSNET database determined that 41% of all proven Candida infections were BT candidiasis and that lung transplant recipients had the highest rates of BT infection.”
BackgroundSpec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz277 · Cited by 88
Self-citationFan, X., Xiao, M., Liao, K., Kudinha, T., Wang, H., Zhang, L., Hou, X., Kong, F., & Xu, Y.-C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00464 · Cited by 85
Candida auris Invasive Infections during a COVID-19 Case Surge
Hanson, B. M., Dinh, A. Q., Tran, T. T., Arenas, S., Pronty, D., Gershengorn, H. B., Ferreira, T., Arias, C. A., & Shukla, B. S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01146-21 · Cited by 81
Antifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81 · cited 1×
“86 As such, therapeutic drug monitoring, especially for itraconazole, voriconazole and posaconazole, is recommended even in the setting of antifungal prophylaxis.”
BackgroundStemler, J., de Jonge, N., Skoetz, N., Sinkó, J., Brüggemann, R. J., Busca, A., Ben‐Ami, R., Ráčil, Z., Piechotta, V., Lewis, R., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00073-4 · Cited by 79 · cited 1×
“87 It is also crucial to recognize that some commonly use agents have limited penetration into critical spaces.”
BackgroundInvasive Fungal Infections in the Intensive Care Unit
Ostrosky-Zeichner, L., & Al-Obaidi, M. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.05.005 · Cited by 76
Self-citationSpecificity Influences in (1→3)-β-d-Glucan-Supported Diagnosis of Invasive Fungal Disease
Finkelman, M. A. (2020) · Journal of Fungi · doi:10.3390/jof7010014 · Cited by 76
Winston, D. J., Bartoni, K., Territo, M. C., & Schiller, G. J. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.04.017 · Cited by 73 · cited 1×
“…of BT Candida infections occur in patients receiving antifungal prophylaxis with a triazole antifungal such as fluconazole, voriconazole, posaconazole or isavuconazole, 94–96 but there are also ample reports of individuals who experienced breakthrough infections while receiving an echinocandins.”
BackgroundKhan, Z., Ahmad, S., Al‐Sweih, N., Mokaddas, E. M., Al-Banwan, K., Alfouzan, W. A., Al‐Obaid, I., Alobaid, K., Asadzadeh, M., Jeragh, A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216250 · Cited by 69 · cited 1×
“104 For the purposes of this discussion, antifungal susceptibility is determined on the basis of CLSI and/or EUCAST methodologies, and while these methodologies and breakpoints are not entirely interchangeable, there is enough similarity to allow for general comparisons.”
MethodMazi, P. B., Olsen, M. A., Stwalley, D., Rauseo, A. M., Ayres, C., Powderly, W. G., & Spec, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac004 · Cited by 68
Update on the Pathogenesis, Virulence, and Treatment of Candida auris
Watkins, R. R., Gowen, R., Lionakis, M., & Ghannoum, M. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i2.535 · Cited by 68
Garcia-Bustos, V., Cabañero-Navalon, M. D., Ruiz-Gaitán, A., Salavert, M., Tormo-Mas, M. Á., & Pemán, J. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.03.016 · Cited by 68 · cited 2×
“70,71,73 As a result, C. auris has”
BackgroundBrüggemann, R. J., Verheggen, R., Boerrigter, E., Stanzani, M., Verweij, P. E., Blijlevens, N. M. A., & Lewis, R. E. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00232-5 · Cited by 67 · cited 1×
“88”
Riera, F. O., Caeiro, J. P., Angiolini, S. C., Vigezzi, C., Rodriguez, E., Icely, P. A., & Sotomayor, C. E. (2022) · Antibiotics · doi:10.3390/antibiotics11070877 · Cited by 65
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad256 · Cited by 65
Self-citationBizerra, F. C., Jimenez-Ortigosa, C., Souza, A. C. R., Breda, G. L., Queiroz-Telles, F., Perlin, D. S., & Colombo, A. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02189-13 · Cited by 63
Ning, Y., Xiao, M., Perlin, D. S., Zhao, Y., Lu, M., Li, Y., Luo, Z., Dai, R., Li, S., Xu, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2153086 · Cited by 63
Kabbara, N., Lacroix, C., Peffault de Latour, R., Socie, G., Ghannoum, M., & Ribaud, P. (2008) · Haematologica · doi:10.3324/haematol.11149 · Cited by 61 · cited 1×
“93 The majority of BT Candida infections occur in patients receiving antifungal prophylaxis with a triazole antifungal such as fluconazole, voriconazole, posaconazole or isavuconazole, 94–96 but there are also ample reports of individuals who experienced breakthrough infections while receiving an…”
BackgroundAn update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections
Jenks, J. D., White, P. L., Kidd, S. E., Goshia, T., Fraley, S. I., Hoenigl, M., & Thompson, G. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2267977 · Cited by 61
Self-citationPfaller, M. A., Carvalhaes, C. G., Smith, C. J., Diekema, D. J., & Castanheira, M. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115016 · Cited by 59
International Multicentre Study of Candida auris Infections
Pandya, N., Cag, Y., Pandak, N., Pekok, A. U., Poojary, A., Ayoade, F., Fasciana, T., Giammanco, A., Caskurlu, H., Rajani, D. P., et al. (2021) · Journal of Fungi · doi:10.3390/jof7100878 · Cited by 56
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection
Shields, R. K., Nguyen, M. H., Press, E. G., Cumbie, R., Driscoll, E., Pasculle, A. W., & Clancy, C. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01973-15 · Cited by 55
Race and ethnicity: Risk factors for fungal infections?
Jenks, J. D., Aneke, C. I., Al-Obaidi, M. M., Egger, M., Garcia, L., Gaines, T., Hoenigl, M., & Thompson, G. R. (2023) · PLOS Pathogens · doi:10.1371/journal.ppat.1011025 · Cited by 55
Self-citationRisk factors and outcome for nosocomial breakthrough candidaemia
Pasqualotto, A. C., Nedel, W. L., Machado, T. S., & Severo, L. C. (2006) · Journal of Infection · doi:10.1016/j.jinf.2005.04.020 · Cited by 54 · cited 1×
“83 While any of these factors can enhance the risk of BT infection in any of these three major patient groups, they are profoundly impactful and potentially synergistic in the ICU population.”
BackgroundTrevijano-Contador, N., Torres-Cano, A., Carballo-González, C., Puig-Asensio, M., Martín-Gómez, M. T., Jiménez-Martínez, E., Romero, D., Nuvials, F. X., Olmos-Arenas, R., Moretó-Castellsagué, M. C., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac605 · Cited by 54
Machado, M., Estévez, A., Sánchez-Carrillo, C., Guinea, J., Escribano, P., Alonso, R., Valerio, M., Padilla, B., Bouza, E., & Muñoz, P. (2022) · Journal of Fungi · doi:10.3390/jof8030305 · Cited by 53
Chen, P.-Y., Chuang, Y.-C., Wu, U.-I., Sun, H.-Y., Wang, J.-T., Sheng, W.-H., Lo, H.-J., Wang, H.-Y., Chen, Y.-C., & Chang, S.-C. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190520 · Cited by 51
Hoenigl, M., Egger, M., Price, J., Krause, R., Prattes, J., & White, P. L. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01859-22 · Cited by 51
Self-citationThe epidemiology of Candida species in the Middle East and North Africa
Ghazi, S., Rafei, R., Osman, M., El Safadi, D., Mallat, H., Papon, N., Dabboussi, F., Bouchara, J.-P., & Hamze, M. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.07.006 · Cited by 50
Breakthrough candidaemia in the era of broad-spectrum antifungal therapies
Cuervo, G., Garcia-Vidal, C., Nucci, M., Puchades, F., Fernández-Ruiz, M., Obed, M., Manzur, A., Gudiol, C., Pemán, J., Aguado, J. M., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.09.029 · Cited by 49
Jenks, J. D., Gangneux, J.-P., Schwartz, I. S., Alastruey-Izquierdo, A., Lagrou, K., Thompson III, G. R., Lass-Flörl, C., Hoenigl, M., & Investigators, E. C. O. M. M. (. C. (2020) · Journal of Fungi · doi:10.3390/jof6040216 · Cited by 44
Self-citationDesnos-Ollivier, M., Lortholary, O., Bretagne, S., & Dromer, F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-20 · Cited by 44 · cited 1×
“27,62,102,103,109 In many parts of the world, C. glabrata is the second most common cause of IC, particularly affecting older individuals and those with significant underlying immunosuppression.”
BackgroundOptimization of MALDI-ToF mass spectrometry for yeast identification: a multicenter study
Normand, A., Gabriel, F., Riat, A., et al. (2019) · Medical Mycology · doi:10.1093/mmy/myz098 · Cited by 43 · cited 1×
“15 Blood cultures, however, are positive in only 21–71% of patients later proven by autopsy to have IC.”
BackgroundArastehfar, A., Hilmioğlu-Polat, S., Daneshnia, F., Hafez, A., Salehi, M., Polat, F., Yaşar, M., Arslan, N., Hoşbul, T., Ünal, N., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.587278 · Cited by 40 · cited 2×
“62,66 Summarizing all of Europe together, the increase in the proportion of C. glabrata between 2006–2008 (13.8”
BackgroundInfluentialUpdate on invasive fungal infections in the Middle Eastern and North African region
Osman, M., Al Bikai, A., Rafei, R., Mallat, H., Dabboussi, F., & Hamze, M. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00325-x · Cited by 39
Papadimitriou-Olivgeris, M., Kolonitsiou, F., Kefala, S., Spiliopoulou, A., Aretha, D., Bartzavali, C., Siapika, A., Marangos, M., & Fligou, F. (2022) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2022.102353 · Cited by 39
Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey
Adam, K.-M., Osthoff, M., Lamoth, F., Conen, A., Erard, V., Boggian, K., Schreiber, P. W., Zimmerli, S., Bochud, P.-Y., Neofytos, D., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab471 · Cited by 37
Risum, M., Astvad, K., Johansen, H. K., Schønheyder, H. C., Rosenvinge, F. S., Knudsen, J. D., Hare, R. K., Datcu, R., Røder, B. L., Antsupova, V. S., et al. (2021) · Journal of Fungi · doi:10.3390/jof7060491 · Cited by 36 · cited 1×
“25,40,41,55,61 Comparatively, the proportion of C. parapsilosis has increased in Asia (including Japan and China), Latin America (including Brazil) and Southern Europe, 31,62–65 and the proportion of C. tropicalis has increased particularly in Latin America, and large parts of Asia.”
BackgroundKaerger, K., Schwartze, V. U., Dolatabadi, S., Nyilasi, I., Kovács, S. A., Binder, U., Papp, T., Hoog, S. D., Jacobsen, I. D., & Voigt, K. (2015) · Virulence · doi:10.1080/21505594.2015.1029219 · Cited by 35
Chong, Y., Ito, Y., Kamimura, T., Shimoda, S., Miyamoto, T., Akashi, K., Yakushiji, H., & Shimono, N. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0412-9 · Cited by 35
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35 · cited 1×
“150,156 Ibrexafungerp is another novel agent which inhibits (1→3)-β-D-glucan synthesis at a different site than echinocandins and thus retains activity against many organisms with echinocandin resistance due to FKS mutations, including many strains of C. auris .”
BackgroundDíaz-García, J., Gómez, A., Machado, M., Alcalá, L., Reigadas, E., Sánchez-Carrillo, C., Pérez-Ayala, A., Gómez-García De La Pedrosa, E., González-Romo, F., Cuétara, M. S., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac288 · Cited by 35
Chen, X.-C., Xu, J., & Wu, D.-P. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1523 · Cited by 32 · cited 1×
“97,98 Outcomes If recognized early and managed appropriately, most BT Candida infections can be treated successfully with antifungal therapy including optimization of dosing, source control, and recognizing potential drug-drug interactions.”
BackgroundInvestigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · cited 1×
“149,157 Clinical trials for infections refractory to other agents have been promising.”
BackgroundSelf-citationChumpitazi, B. F. F., Lebeau, B., Faure-Cognet, O., Hamidfar-Roy, R., Timsit, J.-F., Pavese, P., Thiebaut-Bertrand, A., Quesada, J.-L., Pelloux, H., & Pinel, C. (2014) · Medical Mycology · doi:10.1093/mmy/myu018 · Cited by 31 · cited 1×
“21 Due to poor performance, this test has not been approved by the US FDA.”
MethodKajihara, T., Yahara, K., Nagi, M., Kitamura, N., Hirabayashi, A., Hosaka, Y., Abe, M., Miyazaki, Y., & Sugai, M. (2022) · Medical Mycology · doi:10.1093/mmy/myac071 · Cited by 29
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
McCarthy, M. W. (2022) · Drugs in R&D · doi:10.1007/s40268-021-00376-x · Cited by 28
Meyahnwi, D., Siraw, B. B., & Reingold, A. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07848-8 · Cited by 28 · cited 1×
“27,51,52 In Europe, the 30-day mortality rate of IC was slightly higher at 38–42%.”
BackgroundGuo, L., Yu, S.-Y., Xiao, M., Yang, C.-X., Bao, C., Yu, Y., Ye, L., Yang, Y., Zhang, G., Liu, J., et al. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s255843 · Cited by 25 · cited 2×
“109 In multiple population studies over the last two decades, C. albicans is almost uniformly susceptible to fluconazole, the echinocandins, and amphotericin B. Resistance to fluconazole is uncommon, with rates generally ranging between 0% and 3%, but averaging less than 1% overall.”
BackgroundKim, S.-H., Choi, J.-K., Cho, S.-Y., Lee, H.-J., Park, S. H., Choi, S.-M., Lee, D.-G., Choi, J.-H., Yoo, J.-H., & Lee, J.-W. (2018) · Medical Mycology · doi:10.1093/mmy/myx038 · Cited by 24
Antifungal Susceptibility of Yeasts and Filamentous Fungi by CLSI Broth Microdilution Testing
Wiederhold, N. P. (2023) · Methods in Molecular Biology · doi:10.1007/978-1-0716-3155-3_1 · Cited by 22 · cited 1×
“105,106 Each of the five major species and C. auris will be reviewed.”
BackgroundMcCarty, T. P., Lockhart, S. R., Moser, S. A., Whiddon, J., Zurko, J., Pham, C. D., & Pappas, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky059 · Cited by 21 · cited 1×
“114 Taken as a whole, there has been a slow but steady increase in resistance rates to both fluconazole and the echinocandins over the last two decades and continued assessment of this ongoing problem is essential.”
BackgroundSelf-citationSuzuki, H., Perencevich, E. N., Diekema, D. J., Livorsi, D. J., Nair, R., Kralovic, S. M., Roselle, G. A., & Goto, M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab105 · Cited by 20
Orasch, C., Mertz, D., Garbino, J., van Delden, C., Emonet, S., Schrenzel, J., Zimmerli, S., Damonti, L., Mühlethaler, K., Imhof, A., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2017.12.018 · Cited by 19
Sfeir, M. M., Jiménez-Ortigosa, C., Gamaletsou, M. N., Schuetz, A. N., Soave, R., Van Besien, K., Small, C. B., Perlin, D. S., & Walsh, T. J. (2020) · Journal of Fungi · doi:10.3390/jof6010020 · Cited by 19
Breakthrough Candida Infections in Patients Receiving Voriconazole
Gerzenshtein, L., Patel, S. M., Scarsi, K. K., Postelnick, M. J., & Flaherty, J. P. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e627 · Cited by 15 · cited 1×
“…of BT Candida infections occur in patients receiving antifungal prophylaxis with a triazole antifungal such as fluconazole, voriconazole, posaconazole or isavuconazole, 94–96 but there are also ample reports of individuals who experienced breakthrough infections while receiving an echinocandins.”
BackgroundDesnos-Ollivier, M., Bretagne, S., Lortholary, O., Dromer, F., & the French Mycoses Study Group N. Brieu CH Aix, T. C. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01725-21 · Cited by 13
Zahedi, N., Kenari, S. A., Aslani, N., Ansari, S., Mohseni, S., & Badali, H. (2016) · Current Medical Mycology · doi:10.18869/acadpub.cmm.2.3.15 · Cited by 11
Infection Control Measures against Candidaauris in Healthcare Facilities
Alfouzan, W. A., Dhar, R., Alabbad, J., & Rabaan, A. A. (2022) · Processes · doi:10.3390/pr10081625 · Cited by 10
Predisposition of COVID-19 patients to secondary infections: set in stone or subject to change?
Sopirala, M. M. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000736 · Cited by 8
(2020) · PubMed · Cited by 5
Critical care infections and antimicrobial resistance are complex multifactorial problems
Chakrabarti, A., Sood, P., & Rudramurthy, S. M. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3652-1 · Cited by 3 · cited 2×
“118 Among the five most common Candida species causing invasive candidiasis, C. parapsilosis is the least virulent with respect to all-cause mortality.”
Background
Research works printed but not linked: 2
- Ulrych, 2020, Epidemiol Mikrobiol Imunol, 69, 57
- 2020, Clinical Practice of Medical Mycology in Asia
Cited by
Candida auris: Epidemiology Update and a Review of Strategies to Prevent Spread
Hayes, J. F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226675 · Cited by 45
Biofilm Formation as a Pathogenicity Factor of Medically Important Fungi
Vila, T. V. M., & Rozental, S. (2016) · InTech eBooks · doi:10.5772/62768 · Cited by 30
Growth defects resulting from inhibiting ERG20 and RAM2 in Candida glabrata
Nakayama, H., Ueno, K., Uno, J., Nagi, M., Tanabe, K., Aoyama, T., Chibana, H., & Bard, M. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02205.x · Cited by 22
Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy
Martín‐Loeches, I., Cornely, O. A., Denning, D. W., Guinea, J., Bassetti, M., Maertens, J. A., Hoenigl, M., Kanj, S. S., Slavin, M. A., Ostrosky-Zeichner, L. L., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08151-1 · Cited by 23
Self-citationThe impact of phenotypic heterogeneity on fungal pathogenicity and drug resistance
Kozubowski, L., & Berman, J. G. (2025) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf001 · Cited by 14
Metadata
- Authors
- Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G.
- Affiliations
- University of California Davis Medical Center (US)
- Centers for Disease Control and Prevention (US)
- The University of Texas Health Science Center at Houston (US)
- Medical University of Graz (AT)
- University of Alabama at Birmingham (US)
- Corresponding author
- Bays, Derek
- ORCID
- Venue
- Clinical Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2024-08
- Volume
- Volume 16
- Pages
- 549-566
- ISSN
- 1179-1349 (ISSN-L)
- PMC
- PMC11366240
- OpenAlex
- W4401967436
- Cited by
- 109
- References
- 165
- Citations by year
- 2026: 62 · 2025: 42 · 2024: 2
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Epidemiology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (UL1TR001860, KL2TR001859)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- invasive candidiasis, Candida albicans, non-albicans Candida, Candida auris, antifungal resistance, opportunistic fungal infection, emerging fungal pathogens, antifungal agents, nosocomial transmission, cancer patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
